Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance
Authors:
- 25 July 2025
- journal article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (9) , 2503-2512
Abstract
Objectives: French imipenemase (FRI) is a carbapenemase that confer a wide range of MICs of carbapenems in blaFRI-harbouring isolates. In some isolates, duplication of the blaFRI-containing region is reported with high carbapenem MICs. A clinical Enterobacter asburiae isolate harbouring blaFRI-9 on plasmid showed high-level carbapenem resistance. This study aimed to prove that this high-level carbapenem resistance is attributed to antimicrobial-induced duplication of blaFRI-9. Methods: Carbapenem-resistant and carbapenem-susceptible revertants derived from the clinical isolate were selected by culturing with and without antimicrobials, respectively. WGS was performed to identify the genetic background of those strains. The number of repeats of the 35 422-bp region surrounding blaFRI-9, designated as the FRI-9–long repeat region (FRI9-LR), was estimated by the ratio of the average sequence depth of FRI9-LR to that of other regions excluding FRI9-LR. Results: Revertants obtained by culturing with and without antimicrobials, resulting in strains with varying carbapenem MICs. WGS revealed correlation between the number of repeats of FRI9-LR and the carbapenem MICs. Exposing the carbapenem-susceptible revertant to ampicillin did not increase the number of FRI9-LR repeats and only minimally increased the carbapenem MICs, possibly due to overexpression of AmpC β-lactamase. However, exposure to meropenem after ampicillin significantly increased both the number of FRI9-LR repeats and the carbapenem MIC, resulting in multidrug resistance. Conclusions: The high-level carbapenem resistance in this clinical isolate was attributed to multiple duplications of FRI9-LR. Furthermore, the flexibility in the duplication of this region resulted in changes in antimicrobial susceptibility, without loss or acquisition of resistance genes.Keywords
Funding Information
- Research Program on Emerging and Re-emerging Infectious Diseases of the Japan Agency for Medical Research and Development (22fk0108604j0102, 23fk0108604j0103, 24fk0108699j0101, 25fk0108699h0002)
This publication has 27 references indexed in Scilit:
- Emergence of rare carbapenemases (FRI, GES-5, IMI, SFC and SFH-1) in Enterobacterales isolated from surface waters in JapanJournal of Antimicrobial Chemotherapy, 2022
- Characterization of FRI carbapenemase-producing Enterobacter spp. isolated from a hospital and the environment in Osaka, JapanJournal of Antimicrobial Chemotherapy, 2021
- Twelve years of SAMtools and BCFtoolsGigaScience, 2021
- Dissemination of IncF group F1:A2:B20 plasmid-harbouring multidrug-resistant Escherichia coli ST131 before the acquisition of blaCTX-M in JapanJournal of Global Antimicrobial Resistance, 2020
- Mechanisms and clinical relevance of bacterial heteroresistanceNature Reviews Microbiology, 2019
- Assembly of long, error-prone reads using repeat graphsNature Biotechnology, 2019
- The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplificationNature Microbiology, 2019
- DFAST: a flexible prokaryotic genome annotation pipeline for faster genome publicationBioinformatics, 2017
- Conserved Features in the Structure, Mechanism, and Biogenesis of the Inverse Autotransporter Protein FamilyGenome Biology and Evolution, 2016
- Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomesDiagnostic Microbiology and Infectious Disease, 2013